+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P04140(NBEA Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04140(NBEA Antibody) at dilution 1/60. (Original magnification: ×200)    

  
  

The Neurobeachin (NBEA) antibody is a tool used to study the NBEA protein, a member of the BEACH (Beige and Chediak-Higashi) domain-containing protein family. NBEA is primarily expressed in the brain and plays a critical role in synaptic vesicle trafficking, neurotransmitter release, and neuronal signaling. It is implicated in regulating postsynaptic receptor composition and synaptic plasticity, processes essential for learning and memory. The gene encoding NBEA is located on chromosome 13q13.3 and has been linked to neurodevelopmental disorders, including autism spectrum disorders (ASD) and intellectual disability, through genetic studies identifying deletions or mutations in affected individuals.

NBEA antibodies are widely utilized in neuroscience research to investigate protein localization, expression levels, and molecular interactions. They help elucidate NBEA's role in neuronal development, synaptic function, and disease mechanisms. For example, studies using these antibodies have revealed NBEA's involvement in the trafficking of glutamate receptors and its interaction with cytoskeletal components. Commercially available NBEA antibodies are typically validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence, often targeting specific epitopes within the protein's conserved regions. As NBEA is a large protein (~300 kDa), proper antibody validation is crucial to ensure specificity. Ongoing research aims to clarify its potential as a therapeutic target or biomarker for neuropsychiatric conditions.